Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapeutics

Background:

• Antibody-targeted nanoparticles show potential for cancer treatment.
• Developmental challenges with antibody components hinder clinical translation.

Purpose of the Study:

• To develop a robust strategy for engineering an EphA2-targeting antibody fragment for immunoliposomal drug delivery.
• To overcome developmental liabilities of antibody fragments, such as low stability and poor binding.

Main Methods:

• Engineered a single-chain variable fragment (scFv) for enhanced bioactivity.
• Modified the scFv framework to improve thermostability.
• Altered the complementarity-determining region (CDR)-H2 to enhance binding to protein A resins for purification.

Main Results:

• Achieved significantly improved thermostability of the antibody fragment.
• Enhanced the binding affinity to protein A resins, facilitating purification.
• Demonstrated a viable strategy for rapid improvement of antibody fragment characteristics.

Conclusions:

• Focused engineering strategies can rapidly enhance antibody fragment stability and manufacturing properties.
• The developed EphA2-targeting scFv is suitable for novel therapeutic constructs.
• This approach facilitates the clinical development of antibody-targeted nanoparticle drug delivery systems.